{
  "abstract": "Purpose\n\nMepolizumab reduces exacerbations in patients with chronic obstructive pulmonary disease (COPD) and was recently approved in the United States (US) for the add-on maintenance treatment of adult patients with inadequately controlled COPD and an eosinophilic phenotype. Given the limited real-world data on mepolizumab effectiveness in COPD, this study assessed its real-world impact in patients with COPD, prior to US regulatory approval of mepolizumab for COPD.Patients and methods\n\nRetrospective, longitudinal analysis from the US Komodo Research claims database (January 2016-June 2024). The first observed mepolizumab claim was defined as the index date. All patients were aged ≥40 years on index date, had ≥2 COPD diagnosis claims in the 12 months pre-index (baseline period) or on index date, and required ≥2 pharmacy/medical claims for mepolizumab from index date to end of observation. Patients with ≥2 asthma diagnosis claims or ≥1 diagnosis claim(s) for cystic fibrosis, lung cancer, interstitial lung disease, or α-1 antitrypsin deficiency during the baseline period or on index date were excluded. Outcomes assessed during the 12 months post- versus 12 months pre-mepolizumab initiation included annualized exacerbation rates, oral corticosteroid (OCS) use, and COPD-related healthcare resource utilization (HCRU).Results\n\nDescriptive analyses included 693 mepolizumab initiators (58% Medicare), while pre-post analyses included 470 patients with 12 months of pre- and post-initiation data. Annualized rate of moderate/severe exacerbations decreased by 41% (P<0.001) post- versus pre-mepolizumab. Relative reductions of 26% and 33% in rates of OCS dispensing and bursts were observed (P<0.001), and relative reductions of 22-37% in COPD-related HCRU including hospitalizations (P=0.038), emergency department visits (P<0.001), and outpatient visits (P<0.001).Conclusion\n\nIn this real-world retrospective study of US patients with COPD, initiation of mepolizumab was associated with significant reductions in COPD exacerbations, OCS use and COPD-related HCRU.",
  "abstract_shown": true,
  "affiliations": [
    "Rutgers Institute for Translational Medicine and Science, The State University of New Jersey, New Brunswick, NJ, USA.",
    "Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.",
    "Global Real-World Evidence and Health Outcomes Research, GSK, Collegeville, PA, USA.",
    "US Medical Affairs, R&D Global Medical, GSK, Durham, NC, USA.",
    "Groupe d'analyse SRI, Montréal, QC, Canada.",
    "US Medical Affairs, GSK, Collegeville, PA, USA.",
    "Analysis Group, Ltd, Boston, MA, USA.",
    "Division of Pulmonary Diseases/Critical Care Medicine, University of Texas Health, San Antonio, TX, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Reynold A Panettieri",
      "orcid": "0000-0003-0834-4636"
    },
    {
      "affs": [
        2
      ],
      "name": "Rosirene Paczkowski"
    },
    {
      "affs": [
        2
      ],
      "name": "Hannah Mei"
    },
    {
      "affs": [
        3
      ],
      "name": "Emmeline Burrows"
    },
    {
      "affs": [
        4
      ],
      "name": "Guillaume Germain"
    },
    {
      "affs": [
        5
      ],
      "name": "Sunay Shah"
    },
    {
      "affs": [
        6
      ],
      "name": "Jacob Klimek"
    },
    {
      "affs": [
        4
      ],
      "name": "Sophie Ma"
    },
    {
      "affs": [
        6
      ],
      "name": "Sarah Cooper"
    },
    {
      "affs": [
        4
      ],
      "name": "François Laliberté"
    },
    {
      "affs": [
        7
      ],
      "name": "Antonio Anzueto"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dqenzjhaehgav.bib",
  "cited_by": 0,
  "doi": "10.2147/copd.s623966",
  "fulltext_url": "https://europepmc.org/articles/PMC13695930",
  "id": "dqenzjhaehgav",
  "issns": [
    "1176-9106",
    "1178-2005"
  ],
  "landing_url": "https://europepmc.org/article/MED/42928917",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Chronic Obstructive Pulmonary Disease (COPD) Research"
    ]
  ],
  "openalex": "W7223109392",
  "pdf_url": "https://europepmc.org/articles/PMC13695930?pdf=render",
  "pmcid": "PMC13695930",
  "pmid": "42928917",
  "published": "2026-10-21",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/dqenzjhaehgav.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "MED:42928917",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42928917"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Chronic Obstructive Pulmonary Disease (COPD) Research",
      "subfield": "general"
    }
  ],
  "title": "Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database.",
  "title_text": "Real-World Impact of Mepolizumab in COPD in a US Commercial and Medicare Claims Database.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:18Z",
  "url": "https://research.draconitic.com/paper/dqenzjhaehgav",
  "venue": "International journal of chronic obstructive pulmonary disease",
  "versions": []
}